Makers Laboratories Ltd Upgraded to Sell on Technical Improvements and Mixed Fundamentals

Technical Trend Shift Spurs Upgrade

The most significant catalyst behind the rating change was the improvement in Makers Laboratories’ technical outlook. The technical grade transitioned from mildly bearish to sideways, signalling a stabilisation in price momentum after a period of decline. Key technical indicators present a mixed but cautiously optimistic picture. On a weekly basis, the Moving Average Convergence Divergence (MACD) is bullish, while the monthly MACD remains bearish, reflecting short-term strength amid longer-term caution.

Similarly, Bollinger Bands suggest mild bullishness weekly and outright bullishness monthly, indicating that price volatility is supporting upward movement. The Relative Strength Index (RSI) on both weekly and monthly charts shows no clear signal, implying a neutral momentum stance. The Know Sure Thing (KST) indicator is bullish weekly but bearish monthly, reinforcing the notion of short-term recovery against a longer-term downtrend.

Daily moving averages remain mildly bearish, and Dow Theory analysis shows no clear weekly trend but a mildly bullish monthly trend. These mixed signals collectively suggest that while the stock is not yet in a strong uptrend, the technical deterioration has paused, justifying the upgrade from Strong Sell to Sell.

Financial Trend: Mixed Quarterly Gains Amid Long-Term Weakness

Financially, Makers Laboratories reported a strong quarter in Q3 FY25-26, with Profit Before Tax less Other Income (PBT less OI) rising 152.9% to ₹2.82 crores compared to the previous four-quarter average. Net sales reached a quarterly high of ₹35.67 crores, while Profit Before Depreciation, Interest and Tax (PBDIT) also peaked at ₹4.16 crores. These figures indicate a short-term operational improvement and suggest the company is gaining some traction in its core business.

However, the longer-term financial trend remains concerning. The company has experienced a negative compound annual growth rate (CAGR) of -15.78% in operating profits over the past five years, signalling deteriorating profitability. Return on Equity (ROE) averaged a mere 2.20%, reflecting low efficiency in generating shareholder returns. Over the last year, despite a stock price return of 7.95%, profits have plummeted by 82.7%, underscoring the disconnect between market performance and underlying earnings.

Valuation Remains a Key Concern

Makers Laboratories’ valuation metrics continue to be a drag on its investment appeal. The stock trades at a Price to Book (P/B) ratio of 1.3, which is considered very expensive relative to its peers and historical averages. This premium valuation is difficult to justify given the company’s weak profitability and negative long-term growth trajectory. The micro-cap status further adds to the risk profile, as smaller companies often face greater volatility and liquidity constraints.

Investors should note that despite the recent price correction of -3.82% on the day, the stock remains near its 52-week high of ₹173.70, trading currently at ₹150.00. The 52-week low stands at ₹109.00, indicating a wide trading range and heightened price uncertainty.

Comparative Performance Against Benchmarks

When compared to the broader market, Makers Laboratories has delivered mixed returns. Over the past week, the stock declined by 3.13%, slightly outperforming the Sensex’s 3.72% fall. Over one month, the stock gained 5.34%, significantly outperforming the Sensex’s 12.72% decline. Year-to-date returns are robust at 26.96%, contrasting with the Sensex’s negative 14.70%. Over one year, the stock returned 7.95% while the Sensex fell 5.47%. Over three years, Makers Laboratories outperformed with a 45.63% gain versus the Sensex’s 25.50%.

However, the five-year return of -42.21% starkly contrasts with the Sensex’s 45.24% gain, highlighting the company’s struggles over the medium term. Over ten years, the stock has appreciated 143.70%, trailing the Sensex’s 186.91% rise, indicating underperformance in the long run.

Quality Assessment: Low Profitability and Shareholder Returns

The company’s quality rating remains weak, with an average ROE of just 2.20%, signalling limited profitability per unit of shareholder equity. This low return is a critical factor in the overall Sell rating, as it suggests that the company is not efficiently deploying capital to generate earnings growth. The weak long-term operating profit trend further undermines confidence in the company’s ability to sustain growth or improve margins.

Technical Outlook and Market Sentiment

The technical upgrade reflects a stabilisation in market sentiment after a period of bearishness. The weekly bullish MACD and KST indicators, combined with bullish Bollinger Bands on the monthly chart, suggest that the stock may be forming a base for a potential recovery. However, the presence of bearish monthly MACD and KST, alongside mildly bearish daily moving averages, indicates that any upside remains tentative and should be approached with caution.

Market participants should also consider the stock’s micro-cap classification, which often entails higher volatility and lower liquidity. The majority shareholding by promoters may provide some stability, but it also concentrates control and risk.

Conclusion: Upgrade Reflects Technical Stabilisation, Not Fundamental Improvement

In summary, Makers Laboratories Ltd’s upgrade from Strong Sell to Sell is primarily driven by a technical trend shift from mildly bearish to sideways, signalling a pause in the stock’s decline. While recent quarterly results show encouraging signs of operational improvement, the company’s long-term financial fundamentals remain weak, with declining operating profits, low ROE, and expensive valuation metrics relative to peers.

Investors should weigh the improved technical signals against the persistent fundamental challenges before considering exposure. The stock’s recent outperformance relative to the Sensex in the short and medium term is notable but tempered by its poor five-year returns and profit erosion. As such, the Sell rating reflects a cautious stance, recognising technical progress but acknowledging ongoing risks in valuation and financial health.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →